The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite ...

Novo Nordisk's blockbuster diabetes drug Ozempic will be eligible for U.S. government's price negotiations in less than a ...

A committee report found the weight loss drug is offered for less than $100 in some European countries, compared to monthly ...

Novo Nordisk’s blockbuster type 2 diabetes medication is a sure bet for the list of the next 15 drugs whose Medicare prices ...

During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced tough questions ...

While grilling Novo Nordisk’s chief executive over the price of its blockbuster diabetes and weight-loss drugs, Ozempic and ...

Hidradenitis suppurativa is a lesion-causing inflammatory disorder that affects at least 1 in 100 people and is strongly ...

The CEO of Novo Nordisk is on Capitol Hill Tuesday to testify before a Senate committee about the high costs of its drugs ...

Novo Nordisk charges $969 per month for Ozempic in the U.S., compared ... they don't understand what happens with pricing a ...

The health benefits of blockbuster weight loss drugs are bridging the stark political divide in the United States.

What I am asking you is, if you don’t act, 40,000 people a year could die? Is this acceptable to you?” the senator asked.

No, if Novo Nordisk lowered their list price for Ozempic and Wegovy tomorrow to a price that was the same or lower than current net cost, that change by itself would not result in less favorable ...